Mr. Jin joined the Board in 2020. He is Chief Executive Officer of HLB, which is Elevar’s parent company, and leads HLB Group as Chairman, bringing seasoned leadership and keen insights gained from a broad management background. He is committed to alleviating human disease and suffering by finding new treatments for patients with cancer and other illnesses throughout the world.
Dr. Choi has over 25 years experience in the pharmaceutical industry. He is a successful corporate leader combining a strong background in business development, fundraising, M&A activity, and operations.
Dr. Jang has more than 15 years of experience in the pharmaceutical and medical device industry. His experience includes product and business development, market and company analysis, and project management. He leads the Bio Strategic Planning Team for the HLB Group.
Mr. Dong Gun Kim joined the Board in 2020. He currently serves as both Chief Strategy Officer of Elevar and Chief Executive Officer of HLB. Prior to joining Elevar/HLB, Mr. Kim spent more than 30 years as a specialist in M&A, corporate finance and investment management at leading corporations and professional firms (law, investment banking and private equity) both in the U.S. and Korea. Mr. Kim has an A.B. in Physics from Harvard College and a J.D. from Harvard Law School.
Dr. Chong was appointed to the role of Chief Executive Officer in March 2022 and is a member of the Executive Team. Saeho brings more than 25 years of senior management experience, including more than a decade of strategic development in the pharmaceutical industry.
Dr. Han joined the Board in April 2022. He is the Chief Executive Officer of HLB Life Science and leads all new drug development activities. Yong-Hae has played major roles in multiple R&D organizations in the US and Korea.